Biological Safetry Centre BIOSC, the innovation selected by “Italia degli Innovatori”
The Biological Safety Centre BioSC will take part in the “Italia degli Innovatori 2011/2012” project, an initiative promoted by the Italian Government to showcase an Italy that can do innovation and our country’s excellent technological achievements. BioSC, a centre specialising in viral validation studies which has been working at the Kedrion’s plant in Bolognana (Lucca
Kedrion receives FDA authorisation to sell its Albumin on the US market
Kedrion announces that on 3rd June 2011 it has received from the Food and Drug Administration, the government agency responsible for supervising and authorising the marketing of pharmaceuticals in the United States, the authorisation to sell its albumin on the US market, with the brand name KEDBUMIN. Under such authorisation, Kedrion will produce albumin for
Kedrion reinforces its presence in the US. Closed acquisition of Grifols’ assets. Incorporation of the new Kedrion Biopharma
Kedrion, a biopharmaceutical company specialising in the development, production and distribution of plasma-derived medicinal products, announces that, having received the approval from the US Federal Trade Commission (FTC), it has finalized the transaction previously announced on May 2nd relative to the purchase of certain assets from Grifols S.A. and the commercial and manufacturing agreement between
Agreements between Kedrion and Grifols
Kedrion announces today to have reached an agreement with Grifols S.A. (Grifols) for the sale of Grifols’ assets to Kedrion; the two companies also have established commercial, lease and manufacturing agreements for up to seven (7) years. This agreement has been reached in order to satisfy the conditions for the merger transaction between Grifols and
Fondazione Toscana Life Sciences grants Kedrion a line for small productions at the Tech Park in Siena
Fondazione Toscana Life Sciences, a non-profit organisation specialising in the establishment of new pharmaceutical/biotechnological ventures, and Kedrion, a biopharmaceutical company specialising in the development and manufacture of plasma-derived products, announced they have entered into an agreement under which Kedrion will be granted a biopharmaceutical production laboratory in accordance with the GMPs – Good Manufacturing Practices,
“Safety of blood-derived products”, Kedrion one of the major participants in the 5th edition of Forum Risk Management (Arezzo, Italy)
Kedrion, a biopharmaceutical company specialising in the development, manufacture and distribution of plasma-derived products, is one of the major participants in the fifth edition of Forum on Health Risk Management taking place in Arezzo (Italy) until November 26th. In particular, Kedrion took part in the meeting of November 23rd called “Safety of blood-derived products”, chaired
BioSC, Kedrion’s excellence in the new Biological Safety Centre for viral validation studies
The Biological Safety Centre – BioSC, specialized in viral validation studies, more specifically “studies for inactivation/removal of viral and non-viral pathogens (prions) for biological and biotechnological productions” for in-house and outsourced services, has been opened. BioSC’s mission is to respond with full capabilities to the current and future requirements in terms of safety from biological
Kedrion S.p.A. Board of Directors approves 2009 financial statements
The Board of Directors of Kedrion SpA – specialising in the development, manufacture and distribution of plasma derived medicinal products, led by Paolo Marcucci, President and CEO – met today to approve the 2009 Financial Statements. In the financial year 2009, Kedrion Group achieved some major results, despite the challenging scenario, retaining its leading position
Kedrion received QSEAL certification from PPTA
Kedrion has been awarded Quality Standards of Excellence, Assurance, and Leadership (QSEAL) certification from the Plasma Protein Therapeutics Association (PPTA). The international QSEAL Program relies on independent, third-party evaluation and recognizes strict adherence to a set of voluntary standards, which underscore the industry’s quality and safety commitment to patients who rely on essential plasma protein
Growth of the Kedrion Group: expansion of the Hungarian plant starting now. A new Plasmaphereris centre settled in Budapest
Kedrion Group’s growth strategy is progressing in two directions: one is the vertical integration of its operations, the other is the expansion of its production capacity aimed at consolidating its international market share, especially in Europe. The start of the upgrading and expansion of the Gödöllo plant, commissioned to the Engineering Company Foster Wheeler Italiana
